Inicio › Colitis ulcerativa › Colorado › Colorado Springs
Ensayos clínicos de Colitis ulcerativa en Colorado Springs, CO
14 estudios para Colitis ulcerativa buscan participantes en centros de Colorado Springs y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
ReclutandoFase 2
- Peak Gastroenterology Associates - Colorado Springs - North Cascade Avenue /ID# 280507, Colorado Springs
A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
ReclutandoFase 4
- Peak Gastroenterology Associates, Colorado Springs
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
ReclutandoFase 2
- Peak Gastroenterology Associates, Colorado Springs
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
ReclutandoFase 2
- Site 033, Colorado Springs
A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)
ReclutandoFase 2
- Peak Gastroenterology Associates ( Site 1052), Colorado Springs
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
ReclutandoFase 2
- Peak Gastroenterology Associates, Colorado Springs
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
ReclutandoFase 3
- Peak Gastroenterology Associates, Colorado Springs
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
ReclutandoFase 2
- Peak Gastroenterology Associates, Colorado Springs
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
ReclutandoFase 2
- Peak Gastroenterology Associates, Colorado Springs
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
ReclutandoFase 3
- Peak Gastroenterology Associates - Colorado Springs - Site Number: 8400039, Colorado Springs
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
ReclutandoFase 3
- Peak Gastroenterology Associates, Colorado Springs
A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis
ReclutandoFase 2
- Peak Gastroenterology Associates, Colorado Springs
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
ReclutandoFase 3
- Peak Gastroenterology Associates - Colorado Springs - Site Number: 8400039, Colorado Springs
A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
ReclutandoFase 2
- Mirador Therapeutics Selected Site, Colorado Springs
Más información sobre Colitis ulcerativa en MedlinePlus
Ensayos de Colitis ulcerativa en otras ciudades
- New York City, NY23 estudios
- Orlando, FL22 estudios
- Miami, FL21 estudios
- Houston, TX17 estudios
- San Antonio, TX16 estudios
- Chicago, IL15 estudios
- Tacoma, WA15 estudios
- San Diego, CA15 estudios
- Tyler, TX14 estudios
- Los Angeles, CA13 estudios
- St. Louis, MO13 estudios
- Washington, DC12 estudios
Otros estudios en Colorado Springs
- Enfermedad de Crohn13 estudios
- Cáncer de próstata12 estudios
- Cáncer de pulmón de células no pequeñas11 estudios
- Cáncer de pulmón8 estudios
- Cáncer de seno7 estudios
- Asma6 estudios
- Cáncer del colon y del recto6 estudios
- Cáncer de colon6 estudios
- Carcinoma de células escamosas de cabeza y cuello4 estudios
- Melanoma4 estudios
- Cáncer de recto4 estudios
- Enfermedad inflamatoria intestinal4 estudios
De ClinicalTrials.gov, datos obtenidos el 5 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.